The aim of this study was therefore to examine health care utilization and costs in our recent study with 5,077 insulin-naïve type 2 diabetes patients, after starting treatment with NPH, IG, ID or PM [6]. The gene discussed is INS; the disease is type 2 diabetes mellitus.